Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-71.37M | $-10.70 |
| 2024 | $0.00 | $-74.14M | $-11.39 |
| 2023 | $0.00 | $-156.09M | $-24.00 |
| 2022 | $0.00 | $-223.18M | $-34.46 |
| 2021 | $0.00 | $-156.79M | $-29.60 |
Social Signal Score
Earnings
Mon, Nov 16(in 3 months)
Consensus estimate $-0.17 per share
Typical surprise -0.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.63 vs $-0.35miss
- Fri, May 15$-0.62 vs $-0.62beat
- Fri, Mar 27$-1.21 vs $-2.31beat
- Thu, Nov 13$-2.01 vs $-2.00miss
- Wed, Aug 13$-3.24 vs $-1.72miss
- Tue, May 13$-4.32 vs $-2.02miss
Estimates and results for TIL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
TILhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·1d ago·Neutral
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update. Recent Highlights: Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therap…
View source ↗